A CCA cell line was developed from PDX283, a patient-derived xenograft model from a surgically resected intrahepatic CCA with a FGFR2-AFF4 fusion....Based on these results, we evaluated AXL inhibition as a therapeutic strategy in PDX283 cells utilizing two unique AXL inhibitors, bemcentinib and dubermatinib. Significant effects on cell viability were noted with each inhibitor (IC50 900 nM for bemcentinib, IC50 500 nM for dubermatinib). Both bemcentinib and dubermatinib demonstrated a synergistic effect with pemigatinib on PDX283 cells, with calculated combination indices of 0.355 and 0.433, respectively.